Publications by authors named "Darrell Nix"

Claim this Profile
A
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.
Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro, Darrell Nix

Brain· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans.
Nathalie Rioux, Sherri Smith, Federico Colombo, Amy Kim, W George Lai, Darrell Nix

Xenobiotica· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial.
Dirk von Lewinski, Joseph B Selvanayagam, Richard A Schatz, Bernd Jilma, Jacek Kubica, Darrell Nix

Trials· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial.
Nina Buchtele, Michael Schwameis, Christian Schoergenhofer, Ulla Derhaschnig, Christa Firbas, Darrell Nix

Br J Clin Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Leona E Ling, Jan L Hillson, Renger G Tiessen, Tjerk Bosje, Mattheus Paulus van Iersel, Darrell J Nix

Clin Pharmacol Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
Nathalie Rioux, Amy Kim, Darrell Nix, Todd Bowser, Markus Warmuth

Cancer Chemother Pharmacol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
Johann Bartko, Christian Schoergenhofer, Michael Schwameis, Christa Firbas, Martin Beliveau, Darrell Nix

Clin Pharmacol Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
Eileen M O'Reilly, James Roach, Paul Miller, Kenneth H Yu, Catherine Tjan, Darrell Nix

Oncologist· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain.
Michael A Henry, Dara D Fairchild, Mayur J Patil, Taleen Hanania, Heather S Hain, Darrell Nix

J Oral Facial Pain Headache· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Vijaykumar M Baragi, Gabriel Becher, Alison M Bendele, Ralf Biesinger, Harald Bluhm, Darrell Nix

Arthritis Rheum· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
Chuang Lu, Richard Gallegos, Ping Li, Cindy Q Xia, Sandeepraj Pusalkar, Darrell Nix

Drug Metab Dispos· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Teresa Pekol, J Scott Daniels, Jason Labutti, Ian Parsons, Darrell Nix

Drug Metab Dispos· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Sundar Jagannath, Bart Barlogie, James R Berenson, Seema Singhal, Raymond Alexanian, Darrell Nix

Cancer· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Christos N Papandreou, Danai D Daliani, Darrell Nix, Hong Yang, Timothy Madden

J Clin Oncol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis